The Keap1KD mouse model was also used in studies of metabolic diseases, especially in the context of type 2 diabetes and obesity, where, in addition to its protective role against oxidative-stress damage, Nrf2 can interact with pathways not directly associated with cytoprotection, such as in the hypothalamus, where Nrf2 improves insulin and leptin resistance, preventing the progression of diabetes mellitus [41], or in the liver, where Nrf2 has been described as a potential repressor of hepatic gluconeogenesis and lipogenesis [42]. The gene discussed is NFE2L2; the disease is type 2 diabetes mellitus.